Targeting MCF-7 Cell Line by Listeriolysin O Pore Forming Toxin Fusion with AHNP Targeted Peptide

Authors
Gholamreza Fotoohi-Ardakani 1
Majid Kheirollahi 2
Hossein Zarei Jaliani 3
Mohadese Noorian 4
Hossein Ansariniyia 5
1 Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable Disease and Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan; Department of Medical Genetics, School of Medicine, Protein Engineering Laboratory, Shahidsadoughi University of Medical Sciences, Yazd, Iran
2 Pediatric Inherited Diseases Research Center, Research Institute for Primordial Prevention of Non-communicable Disease and Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
3 Department of Medical Genetics, School of Medicine, Protein Engineering Laboratory, Shahidsadoughi University of Medical Sciences, Yazd, Iran
4 Department of Medical Genetics, Shahid Sadoughi University of Medical Science, Yazd, Iran
5 Department of Immunology, Faculty of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran
Abstract
Background: Tumor-targeting peptides are attracting subjects in cancer therapy. These peptides, which are widely studied, deliver therapeutic agents to the specific sites of tumors. In this study, we produced a new form of recombinant listeriolysin O (LLO) with genetically fused Anti-HER2/neu peptide (AHNP) sequence adding to its C-terminal end. The aim of the study was to engineer this pore-forming toxin to make it much more specific to tumor cells. Materials and Method and Results: Two forms of the toxin (with and without peptide) were subcloned into a bacterial expression plasmid. Subcloning was performed using a polymerase chain reaction (PCR) product as a megaprimer in a quick-change PCR to introduce the whole insert gene into the expression plasmid. After expression of two recombinant forms of LLO in BL21 DE3 cells, purification was performed using Ni-NTA affinity column. MDA-MB-231 and MCF-7 cell lines (as negative and positive controls, respectively) were treated with both LLO toxins to evaluate their cytotoxicity and specificity. The IC50 of LLO on MDA-MB-231 and MCF-7 cells was 21 and 5 ng/ml, respectively. In addition, IC50 for the fusion AHNP-LLO toxin was 140 and 60 ng/ml, respectively. It was found that the cytotoxicity of the new engineered AHNP-LLO toxin has decreased by about 9x compared to the wild-type toxin and the specificity of the AHNP-LLO toxin has been also reduced. Conclusions: Results show that the C-terminal of the LLO should not be modified and it seems that N-terminal of the toxin should be preferred for engineering and adding peptide modules.

Keywords

1.
Chari RV. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98-107.  Back to cited text no. 1
    
2.
Baguley BC. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010;46:308-16.  Back to cited text no. 2
    
3.
Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun 2012;12:14.  Back to cited text no. 3
    
4.
Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013;64:15-29.  Back to cited text no. 4
    
5.
Siberil S, Dutertre CA, Boix C, Teillaud JL. Therapeutic monoclonal antibodies: A little history, a lot of engineering, and Some clinical successes. Transfus Clin Biol 2005;12:114-22.  Back to cited text no. 5
    
6.
Elbakri A, Nelson PN, Abu Odeh RO. The state of antibody therapy. Hum Immunol 2010;71:1243-50.  Back to cited text no. 6
    
7.
Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: Successes, limitations and hopes for the future. Br J Pharmacol 2009;157:220-33.  Back to cited text no. 7
    
8.
Aina OH, Sroka TC, Chen ML, Lam KS. Therapeutic cancer targeting peptides. Biopolymers 2002;66:184-99.  Back to cited text no. 8
    
9.
Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci 2017;24:21.  Back to cited text no. 9
    
10.
Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008;1786:126-38.  Back to cited text no. 10
    
11.
Zhao N, Qin Y, Liu H, Cheng Z. Tumor-targeting peptides: Ligands for molecular imaging and therapy. Anticancer Agents Med Chem 2018;18:74-86.  Back to cited text no. 11
    
12.
Garanger E, Boturyn D, Dumy P. Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 2007;7:552-8.  Back to cited text no. 12
    
13.
Tian X, Aruva MR, Wolfe HR, Qin W, Sauter ER, Thakur ML, et al. Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogene mRNAs. Nucleosides Nucleotides Nucleic Acids 2005;24:1085-91.  Back to cited text no. 13
    
14.
Dharap SS, Wang Y, Chandna P, Khandare JJ, Qiu B, Gunaseelan S, et al. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. Proc Natl Acad Sci U S A 2005;102:12962-7.  Back to cited text no. 14
    
15.
Thundimadathil J. Cancer treatment using peptides: Current therapies and future prospects. J Amino Acids 2012;2012:967347.  Back to cited text no. 15
    
16.
Osborne SE, Brumell JH. Listeriolysin O: From bazooka to Swiss army knife. Philos Trans R Soc Lond B Biol Sci 2017;372. pii: 20160222.  Back to cited text no. 16
    
17.
Kayal S, Charbit A. Listeriolysin O: A key protein of listeria monocytogenes with multiple functions. FEMS Microbiol Rev 2006;30:514-29.  Back to cited text no. 17
    
18.
Köster S, van Pee K, Hudel M, Leustik M, Rhinow D, Kühlbrandt W, et al. Crystal structure of listeriolysin O reveals molecular details of oligomerization and pore formation. Nat Commun 2014;5:3690.  Back to cited text no. 18
    
19.
Bergelt S, Frost S, Lilie H. Listeriolysin O as cytotoxic component of an immunotoxin. Protein Sci 2009;18:1210-20.  Back to cited text no. 19
    
20.
Azadpour M, Karimian M, Kheirandish MH, Asadi-Saghandi A, Imani M, Astani A, et al. Evaluating cytotoxic effects of recombinant fragaceatoxin C pore forming toxin against AML cell lines. Iran J Basic Med Sci 2018;21:878-83.  Back to cited text no. 20
    
21.
Tiwari G, Tiwari R, Sriwastawa B, Bhati L, Pandey S, Pandey P, et al. Drug delivery systems: An updated review. Int J Pharm Investig 2012;2:2-11.  Back to cited text no. 21
    
22.
Parker MW, Feil SC. Pore-forming protein toxins: From structure to function. Prog Biophys Mol Biol 2005;88:91-142.  Back to cited text no. 22
    
23.
Glomski IJ, Gedde MM, Tsang AW, Swanson JA, Portnoy DA. The listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol 2002;156:1029-38.  Back to cited text no. 23
    
24.
Giammarini C, Andreoni F, Amagliani G, Casiere A, Barocci S, Magnani M. High-level expression of the LIsteria monocytogenes listeriolysin O in escherichia coli and preliminary characterization of the purified protein. Protein Expr Purif 2003;28:78-85.  Back to cited text no. 24
    
25.
Churchill RL, Lee H, Hall JC. Rapid purification of recombinant listeriolysin O (LLO) from Escherichia coli. J Ind Microbiol Biotechnol 2005;32:355-63.  Back to cited text no. 25
    
Advanced Biomedical Research
Volume 2019, May
May 2019
Pages 1-6